Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) service company offering end-to-end solutions for ...
Shortly after WuXi AppTec provided an upbeat outlook for 2025, several other WuXi sibling companies are coming forward with ...
WuXi Biologics reports 32.5% North American revenue growth in 2024, driven by deals with BioNTech and Candid Therapeutics, ...
WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received 2025 CDMO Leadership Awards in the ...
WuXi Biologics (2269.HK), a leading global CRDMO, has once again earned top recognition at the 2025 CDMO Leadership Awards, ...
Vietnam Investment Review on MSN4d
WuXi Biologics Named to CDP Water Security "A List" for Second Consecutive YearWuXi Biologics, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it ...
Based on data reported through the CDP 2024 Assessment Questionnaire, WuXi Biologics achieved a score of "A" for Water Security, standing out among over 25,000 companies evaluated. As a ...
Based on data reported through the CDP 2024 Assessment Questionnaire, WuXi Biologics achieved a score of "A" for Water Security, standing out among over 25,000 companies evaluated. As a contributor to ...
The company was ranked top in its industry and received a Top 1% S&P Global Corporate Sustainability Assessment (CSA) Score, marking the third year WuXi Biologics has received this highest level ...
Hong Kong IPO: WuXi Biologics unit eyes up to US$520 million in biotech push WuXi XDC, a 60 per cent-owned unit of WuXi Biologics, could raise as much as US$520 million, including excess share ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback